Combination therapy in hypertension: An Asia-Pacific consensus viewpoint

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 865-874

  Abdul Rahman, Abdul Rashid ^a   Reyes, Eugenio B ^b   Sritara, Piyamitr ^c   Pancholia, Arvind ^d   Phuoc, Dang Van ^e   Tomlinson, Brian ^f  

^a CYBERJAYA UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (Malaysia)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Arihant Hospital and Research Center and Gokuldas Heart Center Department of Medicine and Preventive Cardiology   (India)

^e VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antihypertensive combination therapy; Asia Pacific consensus; Fixed dose combinations; Guidelines; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION;

ANTIHYPERTENSIVE THERAPY; ASIA; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL PRACTICE; CONSENSUS; DIASTOLIC BLOOD PRESSURE; DRUG INDICATION; DRUG PREFERENCE; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); MONOTHERAPY; MORBIDITY; PACIFIC ISLANDER; PRACTICE GUIDELINE; RESISTANT HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS;

ANTIHYPERTENSIVE AGENTS; ASIA; BLOOD PRESSURE; CONSENSUS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 84928185457     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1020368     Document Type: Review

References (64)

1. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. 2009. Available at: http:// www.who.int/healthinfo/global-burden-disease/GlobalHealthRisks-report full.pdf [Last accessed 12 March 2013]
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219
3. Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007;50:991-7
4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
5. Tomlinson B, Dalal JJ, Huang J, et al. The role of beta-blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin 2011;27:1021-33
6. Xi B, Liang Y, Reilly KH, et al. Trends in prevalence, awareness, treatment, and control of hypertension among Chinese adults 1991-2009. Int J Cardiol 2012;158:326-9
7. Cheong AT, Tong SF, Sazlina SG, et al. Blood pressure control among hypertensive patients with and without diabetes mellitus in six public primary care clinics in Malaysia. Asia Pac J Public Health 2013: published online 27 March 2013, doi: 10.1177/1010539513480232
8. Azarisman SM, Aszrin A, Marzuki AO, et al. Blood pressure control among diabetic hypertensives under cardiology follow-up at a regional hospital in rural Malaysia. Southeast Asian J Trop Med Public Health 2010;41:973-81
9. Cai L, Liu A, Zhang L, et al. Prevalence, awareness, treatment, and control of hypertension among adults in Beijing, China. Clin Exp Hypertens 2012;34:45-52
10. Jones DW, Kim JS, Kim SJ, Hong YP. Hypertension awareness, treatment and control rates for an Asian population: results from a national survey in Korea. Ethn Health 1996;1:269-73
11. Katayama S, Inaba M, Morita T, et al. Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000;23:601-5
12. Chew BH, Mastura I, Shariff-Ghazali S, et al. Determinants of uncontrolled hypertension in adult type 2 diabetes mellitus: an analysis of the Malaysian diabetes registry 2009. Cardiovasc Diabetol 2012;11:54. doi: 10.1186/ 1475-2840-11-54
13. Ko SH, Kwon HS, Song KH, et al. Long-term changes of the prevalence and control rate of hypertension among Korean adults with diagnosed diabetes: 1998-2008 Korean National Health and Nutrition Examination Survey. Diabetes Res Clin Pract 2012;97:151-7
14. Wu Y, Tai ES, Heng D, et al. Risk factors associated with hypertension awareness, treatment, and control in a multi-ethnic Asian population. J Hypertens 2009;27:190-7
15. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74
16. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
17. Dusing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag 2010;6:321-5
18. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens 2010;4:90-8
19. Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007;61:1592-602
20. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
21. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
22. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
23. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
24. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012;126:2105-14
25. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124-31
26. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertensionrelated expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P & T : a peer-reviewed journal for formulary management 2008;33:652-66
27. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
28. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634-40
29. NICE. Hypertension-the clinical management of primary hypertension in adults. CG127. 2011. Available at: http://www.guidance.nice.org.uk/CG127 [Last accessed 13 March 2013]
30. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
31. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
32. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
33. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007;120:10-27
34. Cruickshank JM. The Modern Role of Beta-Blockers in Cardiovascular Medicine. Shelton, USA: People's Medical Publishing House, 2011
35. Cruickshank JM. Essential Hypertension. Shelton, USA: People's Medical Publishing House, 2013
36. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
37. Armed Forces Medical College. National Rural Health Mission (NRHM) Hypertension Standard Treatment Guidelines. Available at: http://www. nrhm.gov.in/images/pdf/guidelines/nrhm-guidelines/stg/hypertension.pdf. [Last accessed 13 March 2013]
38. Association of Physicians of India. Indian Hypertension Guidelines II. The Association of Physicians in India. Available at: http://www.apiindia.org/pdf/ hsi-guidelines-ii/managehypert.pdf [Last accessed 15 March 2013]
39. Chiang CE, Wang TD, Li YH, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010;109:740-73
40. Liu LS, Writing Group of Chinese Guidelines for the Management of H. [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi 2011;39:579-615
41. Ministry of Health Malaysia. Clinical Practice Guidelines in Management of Hypertension (3rd Edition). 2008. Available at: http://www.moh.gov.my [Last accessed 15 March 2013]
42. National Heart Foundation of Australia. Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults. Updated December 2010. Availabe at: http://www.heartfoundation.org.au/ Professional-Information/Clinical-Practice/Hypertension [Last accessed 13 March 2013]
43. Abelardo NS, for the Multisectoral Task Force Consensus on the Detection and Management of Hypertension in the Philippines. Philippine Clinical Practice Guidelines on the Detection and Management of Hypertension-2011. Available at: http://www.thefilipinodoctor.com/cpm-pdf/CPM15th%20 HYPERTENSION%20%28PSH%29.pdf [Last accessed 10 September 2014]
44. New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012 (3rd Edition). 2012. Available at: http://www.health.govt.nz/publication/newzealand-primary-care-handbook-2012 [Last accessed 14 March 2013]
45. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3-107
46. Park JB. 2004 Korean Hypertension Treatment Guideline and Its Perspective. Korean Circulation J 2006;36:405-10
47. Singapore MoH. MOH Clinical Practice Guidelines: Hypertension 2/2005. 2005. Available at: http://www.moh.gov.sg/content/dam/moh-web/HPP/ Doctors/cpg-medical/withdrawn/cpg-Hypertension-Jun%202005.pdf [Last accessed 12 June 2013]
48. Thai Hypertension Society. Thai Guidelines on the Treatment of Hypertension Update 2012. Available at: http://www.thaihypertension.org/guideline.html [Last accessed 16 March 2013]
49. Vietnamese Society of Hypertension, Vietnam Heart Association. Guidelines for Diagnosis, Treatment, Prevention of Hypertension 2014. Paper presented at: 1st Vietnam Congress of Hypertension, 17-18 May 2014, Hue City, Vietnam
50. Perhimpunan Dokter Hipertensi Indonesia. Consensus Management of Hypertension 2014. [Konsensus penatalaksanaan hipertensi 2014]. Jakarta: Perhimpunan Dokter Hipertensi Indonesia (InaSH), 2014
51. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
52. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
53. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
54. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
55. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
56. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40
57. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-16
58. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
59. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23-8
60. Tomlinson B. Pharmacokinetic and pharmacodynamic responses to-cardiovascular drugs in Asians. Acta Pharmacological Sinica 1998;19:12-13
61. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002;94:1-26
62. Rasool AH, Rahman AR, Ismail R, et al. Ethnic differences in response to nonselective beta-blockade among racial groups in Malaysia. Int J Clin Pharmacol Ther 2000;38:260-9
63. Sulaiman MN, Rahman AR, Noor AR. Effectiveness of combination therapy with or without diuretics in the treatment of essential hypertension. Asia Pac J Pharmacol 2001;15:17-24
64. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-